Derapi | $7,000,000 | (Feb 4, 2026)
AIRRIVED | $6,100,000 | (Feb 4, 2026)
enclaive | $4,849,418 | (Feb 4, 2026)
Certified by Founder
Lodge
Ratio Therapeutics
start up
United States
- Boston, MA
- 02/12/2021
- Unknown
- $1,500,000
A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancer.
Ratio Therapeutics’ Trillium™ targeting scaffold combines pharmacokinetic modulation with best-in-class chelation technology to create proprietary small molecule targeting agents to attack a broad array of cancer targets. Our compounds accommodate imaging and therapeutic radioisotopes, ie "theranostics". The tunable nature of our platform combined with small-scale imaging trials in patients results in accelerated, de-risked compound selection.
- Industry Pharmaceutical Manufacturing
- Website https://ratiotx.com/
- LinkedIn https://www.linkedin.com/company/rat
ecovia I bio | Undisclosed Amount | (Feb 4, 2026)
MaiaEdge | $20,000,000 | (Feb 4, 2026)
Mitra EV | $27,000,000 | (Feb 4, 2026)
Arbor(US) | $6,300,000 | (Feb 4, 2026)
Graici | $7,500,000 | (Feb 4, 2026)
Prenosis | $20,000,000 | (Feb 3, 2026)
Linq | $20,000,000 | (Feb 3, 2026)
Breezy | $10,000,000 | (Feb 3, 2026)
JJG Machining Group | $30,000,000 | (Feb 3, 2026)